Health utility of patients with established rheumatoid arthritis and its influencing factors: a multi-center study in China.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Arthritis, Rheumatoid*/psychology ; Quality of Life*; Humans ; Female ; Male ; Middle Aged ; China/epidemiology ; Cross-Sectional Studies ; Adult ; Aged ; Surveys and Questionnaires ; Pain Measurement ; Severity of Illness Index

To assess the health utility value (HUV) of Rheumatoid Arthritis (RA) patients and its influencing factors in China. A cross-sectional survey was conducted in 8 tertiary hospitals across four capital-cities. The demographic characteristics, patient-reported outcomes including the HUV got by EQ-5D-5L, clinical characteristics, and clinician-reported outcomes of 171 RA patients were collected both from themselves and their physicians. Both the univariate and multivariate analyses were used to assess the potential factors of EQ-5D-5L HUV of the patients. The mean age of the patients was 50.7 years, with female being 64.9% (n = 111). The mean HUV and EQ visual analogue scale score of all patients were 0.586 and 47.3, respectively. The univariate analysis showed that the patients who were female, older, living in rural areas, with lower education level, advanced disease stage, higher the patient's assessment of arthritis pain visual analogue scale (PtAAP-VAS), the patient's global assessment of disease activity visual analogue scale (PtGADA-VAS), and the Physician's global assessment of disease activity visual analogue scale (PhGADA-VAS) scores had significantly lower EQ-5D-5L HUVs. The multivariate analysis further suggested that older age, female, higher body mass index and higher PtGADA-VAS score were statistically significantly related to lower HUVs. The study provided the HUVs for RA patients with different characteristics and outcomes, which could be used in the economic evaluation of interventions for the RA patients. The identified factors could also assist the health care managing and improving the health-related quality of life on RA patients.
(© 2024. The Author(s).)

Association, C. R. 2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis. Chin. J. Internal Med. 57(04), 242–251 (2018).
Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis. Lancet 388(10055), 2023–2038 (2016). (PMID: 10.1016/S0140-6736(16)30173-827156434)
X-f, Z. E. N. G., S-l, Z. H. U., A-c, T. A. N. & X-p, X. I. E. Disease burden and quality of life of rheumatoid arthritis in china: A systematic review. Chin. J. Evid. Based Med. 13(03), 300–307 (2013).
Finckh, A. et al. Global epidemiology of rheumatoid arthritis. Nat. Rev. Rheumatol. 18(10), 591–602 (2022). (PMID: 36068354)
Yun-shan, Z. et al. A multicenter study of deformity and disabmty in rheumatoid arthritis patients in China. Chin. J. Rheumatol. 17(08), 526–532 (2013).
Jin, S. et al. Chinese Registry of rheumatoid arthritis (CREDIT): II. Prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis. Arthritis. Res. Ther. 19(1), 251 (2017). (PMID: 10.1186/s13075-017-1457-z291416885688621)
Xinping, T., Mengtao, Li. & Xiaofeng, Z. The challenges and opportunities for the management of rheumatoid arthritis in China: an annual report of 2019. Chin. J. Internal Med. 60(7), 593–598 (2021).
Xu, H. & Zhang, H. Ultrasonographic diagnosis of wrist joint disease in early stage of rheumatoid arthritis. China Modern Doctor 55(07), 106–110 (2017).
Demoruelle, M. K. & Deane, K. D. Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis. Curr. Rheumatol. Rep. 14(5), 472–480 (2012). (PMID: 10.1007/s11926-012-0275-1227733873616381)
Branch, C. M. A. R. Guidelines for the diagnosis and treatment of rheumatoid arthritis. Chin. J. Rheumatol. 14(04), 265–270 (2010).
Ghabri, S., Lam, L., Bocquet, F. & Spath, H. M. Systematic literature review of economic evaluations of biological treatment sequences for patients with moderate to severe rheumatoid arthritis previously treated with disease-modifying anti-rheumatic drugs. Pharmacoeconomics 38(5), 459–471 (2020). (PMID: 10.1007/s40273-020-00887-632052376)
Li, J. et al. Real-world cost-effectiveness of infliximab for moderate-to-severe rheumatoid arthritis in a medium-sized city of China. J. Comp. Eff. Res. 6(3), 205–218 (2017). (PMID: 10.2217/cer-2016-008627997219)
Pan, C. W. et al. Valuing health-related quality of life in type 2 diabetes patients in China. Med. Decis. Making 36(2), 234–241 (2016). (PMID: 10.1177/0272989X1560690326400873)
Liu, G. China Guidelines for Pharmacoeconomic Evaluations (China Market Press, 2020).
Zou, Y., Cheung, P. P., Teoh, L. K., Chen, C. & Lahiri, M. Sociodemographic factors as determinants of disease, disability and quality of life trajectories in early rheumatoid arthritis: A multi-ethnic inception cohort study. Int. J. Rheum. Dis. 23(1), 55–64 (2020). (PMID: 10.1111/1756-185X.1374731746145)
Cho, S. K., Kim, D., Jun, J. B., Bae, S. C. & Sung, Y. K. Factors influencing quality of life (QOL) for Korean patients with rheumatoid arthritis (RA). Rheumatol. Int. 33(1), 93–102 (2013). (PMID: 10.1007/s00296-011-2352-622218643)
Katchamart, W., Narongroeknawin, P., Chanapai, W. & Thaweeratthakul, P. Health-related quality of life in patients with rheumatoid arthritis. BMC Rheumatol. 3, 34 (2019). (PMID: 10.1186/s41927-019-0080-9314287406694487)
Munchey, R. & Pongmesa, T. Health-related quality of life and functional ability of patients with rheumatoid arthritis: A study from a tertiary care hospital in Thailand. Value Health Reg. Issues 15, 76–81 (2018). (PMID: 10.1016/j.vhri.2017.08.01229474183)
Hoshi, D. et al. Profiles of EQ-5D utility scores in the daily practice of Japanese patients with rheumatoid arthritis; Analysis of the IORRA database. Mod. Rheumatol. 26(1), 40–45 (2016). (PMID: 10.3109/14397595.2015.105998326052801)
Marra, C. A. et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc. Sci. Med. 60(7), 1571–1582 (2005). (PMID: 10.1016/j.socscimed.2004.08.03415652688)
Lillegraven, S., Kristiansen, I. S. & Kvien, T. K. Comparison of utility measures and their relationship with other health status measures in 1041 patients with rheumatoid arthritis. Ann. Rheum. Dis. 69(10), 1762–1767 (2010). (PMID: 10.1136/ard.2009.12409920448285)
Hu, H., Luan, L., Yang, K. & Li, S. C. Psychometric validation of Chinese health assessment questionnaire for use in rheumatoid arthritis patients in China. Int. J. Rheum. Dis. 20(12), 1987–1992 (2017). (PMID: 10.1111/1756-185X.1283126929002)
Zhang, L. et al. Treatment adherence and disease burden of individuals with rheumatic diseases admitted as outpatients to a large rheumatology center in Shanghai, China. Patient Prefer Adherence 11, 1591–1601 (2017). (PMID: 10.2147/PPA.S144624290751065609799)
Patton, T., Hu, H., Luan, L., Yang, K. & Li, S. C. Mapping between HAQ-DI and EQ-5D-5L in a Chinese patient population. Qual. Life Res. 27(11), 2815–2822 (2018). (PMID: 10.1007/s11136-018-1925-1299743826208580)
Langley, P. C., Mu, R., Wu, M., Dong, P. & Tang, B. The impact of rheumatoid arthritis on the burden of disease in urban China. J. Med. Econ. 14(6), 709–719 (2011). (PMID: 10.3111/13696998.2011.61120121899486)
Öz, N., Gezer, H. H., Cilli Hayıroğlu, S. & Duruöz, M. T. Evaluation of the prognostic nutritional index (PNI) as a tool for assessing disease activity in rheumatoid arthritis patients. Clin. Rheumatol. 43(5), 1461–1467 (2024). (PMID: 10.1007/s10067-024-06927-238466500)
Aletaha, D. et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 62(9), 2569–2581 (2010). (PMID: 10.1002/art.2758420872595)
Zhang, L. et al. The correlations of socioeconomic status, disease activity, quality of life, and depression/anxiety in Chinese patients with rheumatoid arthritis. Psychol. Health Med. 22(1), 28–36 (2017). (PMID: 10.1080/13548506.2016.119881727367831)
Huskisson, E. C. Measurement of pain. Lancet 2(7889), 1127–1131 (1974). (PMID: 10.1016/S0140-6736(74)90884-84139420)
Kaneko, Y. et al. Determinants of patient’s global assessment of disease activity and physician’s global assessment of disease activity in patients with rheumatoid arthritis: A post hoc analysis of overall and Japanese results from phase 3 clinical trials. Mod. Rheumatol. 28(6), 960–967 (2018). (PMID: 10.1080/14397595.2017.142230429278339)
Studenic, P., Radner, H., Smolen, J. S. & Aletaha, D. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum. 64(9), 2814–2823 (2012). (PMID: 10.1002/art.3454322810704)
Association, C. R. Diagnosis and treatment guidelines for rheumatoid arthritis. Chin. J. Rheumatol. 14(04), 265–270 (2010).
Prevoo, M. L. et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38(1), 44–48 (1995). (PMID: 10.1002/art.17803801077818570)
EQ-5D-5L | About [ https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/ ].
Xia, J., Wu, N. W., Ma, T. P., Yu, C. & Li, N. X. Evaluation of reliability and validity of EQ-5D-5L based on residents in southwest China. Sichuan Da Xue Xue Bao Yi Xue Ban 51(5), 691–694 (2020). (PMID: 32975086)
Luo, N. et al. Estimating an EQ-5D-5L value set for China. Value Health 20(4), 662–669 (2017). (PMID: 10.1016/j.jval.2016.11.01628408009)
Association, C. R. Chinese rheumatoid arthritis diagnosis and treatment guide. Chin. J. Internal Med. 57(04), 242–251 (2018).
Zhang, L. et al. Methotrexate (MTX) plus hydroxychloroquine versus MTX plus leflunomide in patients with MTX-resistant active rheumatoid arthritis: A 2-year cohort study in real world. J. Inflamm. Res. 13, 1141–1150 (2020). (PMID: 10.2147/JIR.S282249333763797755368)
Bae, S. C. et al. Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs for at least 6 months. Int. J. Rheum. Dis. 21(5), 1001–1009 (2018). (PMID: 10.1111/1756-185X.1291529878615)
Yang, Z., Busschbach, J., Liu, G. & Luo, N. EQ-5D-5L norms for the urban Chinese population in China. Health Qual Life Outcomes 16(1), 210 (2018). (PMID: 10.1186/s12955-018-1036-2304091376225616)
Xie, S., Wang, D., Wu, J., Liu, C. & Jiang, W. Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health survey. Health Qual. Life Outcomes 20(1), 96 (2022). (PMID: 10.1186/s12955-022-02003-y357104299202323)
Haridoss, M., Bagepally, B. S. & Natarajan, M. Health-related quality of life in rheumatoid arthritis: Systematic review and meta-analysis of EuroQoL (EQ-5D) utility scores from Asia. Int. J. Rheum. Dis. 24(3), 314–326 (2021). (PMID: 10.1111/1756-185X.1406633486900)
Palazzo, C., Nguyen, C., Lefevre-Colau, M. M., Rannou, F. & Poiraudeau, S. Risk factors and burden of osteoarthritis. Ann. Phys. Rehabil. Med. 59(3), 134–138 (2016). (PMID: 10.1016/j.rehab.2016.01.00626904959)
Cross, M. et al. The global burden of hip and knee osteoarthritis: Estimates from the global burden of disease 2010 study. Ann. Rheum. Dis. 73(7), 1323–1330 (2014). (PMID: 10.1136/annrheumdis-2013-20476324553908)
Trouvin, A. P. & Perrot, S. Pain in osteoarthritis. Implications for optimal management. Joint Bone Spine 85(4), 429–434 (2018). (PMID: 10.1016/j.jbspin.2017.08.00228889010)
Park, H. Association between rheumatoid arthritis and health-related quality of life in Korean women aged 50 years and over. Asian J. Pharmaceut. Clin. Res. 10, 372–375 (2017). (PMID: 10.22159/ajpcr.2017.v10i5.17749)

Date Created: 20240619 Date Completed: 20240619 Latest Revision: 20240808

20240809

PMC11187111

10.1038/s41598-024-64772-4

38898097